GLP-1 Weight Loss Statistics 2026
Data-driven insights on GLP-1 weight loss medications, clinical trial outcomes, obesity in the US, and the rise of online telehealth programs.
42%
of US adults live with obesity
Source: CDC, 2026 update
14.9%
average weight loss with semaglutide 2.4 mg over 68 weeks (STEP-1)
Source: Wilding et al., NEJM 2021
20.9%
average weight loss with tirzepatide 15 mg over 72 weeks (SURMOUNT-1)
Source: Rosenstock et al., NEJM 2022
55%
of patients on tirzepatide lost at least 20% of body weight
Source: SURMOUNT-1 data
$1,000+
monthly list price for brand-name GLP-1s without insurance
Source: Pharmacy list prices, 2026
35%
of GLP-1 prescriptions in 2026 are filled via telehealth or compounded programs
Source: Industry estimates
Why GLP-1s matter in 2026
GLP-1 receptor agonists have become the most effective prescription option for chronic weight management. They are reshaping how US adults treat obesity, with telehealth making access easier than ever.
Clinical trial snapshot
- STEP-1: Semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs 2.4% with placebo.
- SURMOUNT-1: Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks, with 55.6% of patients losing ≥20%.
- SURMOUNT-OSA: Tirzepatide reduced sleep apnea severity by 62.8% in adults with obesity.
- SELECT: Semaglutide reduced major cardiovascular events by 20% in adults with overweight or obesity and heart disease.
Cost and access
Brand-name medications remain expensive, while compounded and telehealth programs have expanded access for uninsured and underinsured Americans.
Start a GLP-1 program online
Check your eligibility, get approved by a US-licensed provider, and have medication shipped to your door.
Check my eligibilityMethodology
Statistics are sourced from peer-reviewed clinical trials, FDA labels, CDC obesity data, and published pharmacy pricing. We update this page as new data becomes available.
This page is for educational purposes. Always consult a healthcare provider for personal medical advice. Affiliate links are disclosed.